By Adriano Marchese

 

Bristol Myers Squibb Co. said Wednesday the European Commission has approved its drug nivolumab in combination with cabozantinib as a treatment for patients with advanced renal cell carcinoma.

The New York-based pharmaceutical company said the approval follows a Phase 3 trial result that showed the drug nivolumab, also known as Opdivo, in combination with Cabometyx--cabozantinib--significantly improved overall survival objective response rates compared to sunitinib--another cancer-treatment drug.

 

Write to Adriano Marchese at adriano.marchese@wsj.com

 

(END) Dow Jones Newswires

April 14, 2021 16:43 ET (20:43 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.